PNV 0.42% $2.37 polynovo limited

Ann: Annual Report 2023, page-7

  1. 5,867 Posts.
    lightbulb Created with Sketch. 17378
    The Annual Report leaves no doubt that PolyNovo is open for partnering…

    p.4
    The core NovoSorb technology can support other clinical needs and we are open to partners to help co-develop, commercialise or distribute new products. Building successful partnerships will help PolyNovo reach many more patients sooner than we could do alone.

    p.6
    While we have an amazing technology, smart partnerships will help us amplify and accelerate our global reach and impact…

    We are focused on expanding the possibilities for NovoSorb BTM and NovoSorb MTX in the soft tissue reconstruction space, while maintaining excellence in burns and developing smart partnerships to accelerate our growth….

    We are exploring external alliances to partner and build on our procedural strength in burns, while leveraging other businesses and academia for their expertise

    p.8
    Alliance Potential  - Hernia, Abdominal Wall Reconstruction/ Breast Reconstruction, Augmentation, Aesthetics/ Orthobiologics

    p.20
    PolyNovo’s focus over the next 12 months will be to…..Identify potential partners for indication expansion such as hernia and breast
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
(20min delay)
Last
$2.37
Change
-0.010(0.42%)
Mkt cap ! $1.635B
Open High Low Value Volume
$2.43 $2.43 $2.35 $794.7K 334.8K

Buyers (Bids)

No. Vol. Price($)
30 32445 $2.36
 

Sellers (Offers)

Price($) Vol. No.
$2.37 4952 12
View Market Depth
Last trade - 14.02pm 04/07/2024 (20 minute delay) ?
PNV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.